The emergence of nanoporous materials in lung cancer therapy

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J Clin 2021;71(3):209–249.
   Google Scholar
• A.C Society. Cancer facts & Figures 2021, American Cancer Society (2021) 6–72. USA.
   Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Nawaz K, Webster RM. The non-small-cell lung cancer drug market. Nat Rev Drug Discov. 2016;15(4):229–230.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3.
   PubMed Web of Science ®Google Scholar
• Chaft JE, Rimner A, Weder W, et al. Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021;18(9):547–557.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Hu C, Komaki RR, et al. Long-Term results of NRG oncology RTOG 0617: Standard- Versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non–small-cell lung cancer. J Clin Oncol. 2020;38(7):706–714.
   PubMed Web of Science ®Google Scholar
• Cryer AM, Thorley AJ. Nanotechnology in the diagnosis and treatment of lung cancer. Pharmacol Ther. 2019;198:189–205.
   PubMed Web of Science ®Google Scholar
• Cho EC, Au L, Zhang Q, et al. The effects of size, shape, and surface functional group of gold nanostructures on their adsorption and internalization by cells, small (Weinheim an der Bergstrasse. Germany). 2010;6(4):517–522.
   Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery. Nature Reviews. Drug Discovery. 2021;20(2):101–124.
   PubMed Web of Science ®Google Scholar
• Ding S, Khan AI, Cai X, et al. Overcoming blood–brain barrier transport: Advances in nanoparticle-based drug delivery strategies. Mater Today (Kidlington). 2020;37:112–125.
   PubMedGoogle Scholar
• Gong X, Li J, Tan T, et al. Emerging approaches of cell-based nanosystems to target cancer metastasis. Adv Funct Mater. 2019;29(48):1903441.
   Web of Science ®Google Scholar
• Lin G, Revia RA, Zhang M. Inorganic nanomaterial-mediated gene therapy in combination with other antitumor treatment modalities. Adv Funct Mater. 2021;31(5):2007096.
   PubMed Web of Science ®Google Scholar
• Guan G, Wu M, Han M-Y. Stimuli-Responsive hybridized nanostructures. Adv Funct Mater. 2020;30(2):1903439.
   Web of Science ®Google Scholar
• Johnson KK, Koshy P, Yang J-L, et al. Preclinical cancer theranostics—from nanomaterials to clinic: the missing link. Adv Funct Mater. 2021;31(43):2104199.
   Web of Science ®Google Scholar
• Wang J, Li Z, Wang Z, et al. Nanomaterials for combinational radio–immuno oncotherapy. Adv Funct Mater. 2020;30(30):1910676.
   Web of Science ®Google Scholar
• Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.
   Web of Science ®Google Scholar
• Liao Z-X, Huang K-Y, Kempson IM, et al. Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer. J Control Release. 2020;324:482–492.
   PubMed Web of Science ®Google Scholar
• Ahn SY, Liu J, Vellampatti S, et al. DNA transformations for diagnosis and therapy. Adv Funct Mater. 2021;31(12):2008279.
   PubMed Web of Science ®Google Scholar
• Mangal S, Gao W, Li T, et al. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin. 2017;38(6):782–797.
   PubMed Web of Science ®Google Scholar
• Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276(5320):1868–1872.
   PubMed Web of Science ®Google Scholar
• Mamdouh H, Gaber M, Abd Elwakil M, et al. Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 2017;269:374–392.
   Web of Science ®Google Scholar
• Bayne L, Ulijn R, Halling P. Effect of pore size on the performance of immobilised enzymes. Chem Soc Rev. 2013;42:9000–9010.
   PubMed Web of Science ®Google Scholar
• Rahimi-Gorji M, Van de Sande L, Debbaut C, et al. Intraperitoneal aerosolized drug delivery: Technology, recent developments, and future outlook. Adv Drug Deliv Rev. 2020;160:105–114.
   PubMed Web of Science ®Google Scholar
• Abdelaziz HM, Gaber M, Abd-Elwakil MM, et al. Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 2018;269:374–392.
   PubMed Web of Science ®Google Scholar
• Liu D, Long M, Gao L, Chen Y, Li F, Shi F, Gu N. Nanomedicines Targetting Respiratory Injuries for Pulmonary Disease Management. Adv Funct Mater. 2022; 32:2112258.
   Google Scholar
• Sharifianjazi F, Irani M, Esmaeilkhanian A, et al. Polymer incorporated magnetic nanoparticles: Applications for magnetoresponsive targeted drug delivery. Mater Sci Eng B. 2021;272:115358.
   Web of Science ®Google Scholar
• Vaidya B, Kulkarni NS, Shukla SK, et al. Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics. Int J Pharm. 2020;577:118995.
   PubMedGoogle Scholar
• Pellei M, Del Bello F, Porchia M, et al. Zinc coordination complexes as anticancer agents. Coord Chem Rev. 2021;445:214088.
   Web of Science ®Google Scholar
• Živojević K, Mladenović M, Djisalov M, et al. Advanced mesoporous silica nanocarriers in cancer theranostics and gene editing applications. J Control Release. 2021;337:193–211.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang B, Sun J, et al. Recent advances in porous nanostructures for cancer theranostics. Nano Today. 2021;38:101146.
   PubMed Web of Science ®Google Scholar
• Mast M-P, Modh H, Champanhac C, et al. Nanomedicine at the crossroads – a quick guide for ivivc. Adv Drug Deliv Rev. 2021;179:113829.
   PubMed Web of Science ®Google Scholar
• Yano T, Okamoto T, Fukuyama S, et al. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin Oncol. 2014;5(5):1048–1054.
   PubMedGoogle Scholar
• Danesi R, Pasqualetti G, Giovannetti E, et al. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv Drug Deliv Rev. 2009;61(5):408–417.
   PubMed Web of Science ®Google Scholar
• Zeng-Rong N, Paterson J, Alpert L, et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res. 1995;55(21):4760–4764.
   PubMed Web of Science ®Google Scholar
• Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer. 2002;87(8):825–833.
   PubMed Web of Science ®Google Scholar
• Middleton MR, Dean E, Evans TRJ, et al. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours. Br J Cancer. 2021;125(4):510–519.
   Web of Science ®Google Scholar
• Duan F-G, Wang M-F, Cao Y-B, et al. MicroRNA-421 confers paclitaxel resistance by binding to the KEAP1 3′UTR and predicts poor survival in non-small cell lung cancer. Cell Death Dis. 2019;10(11):821.
   PubMedGoogle Scholar
• Yuan M, Huang -L-L, Chen J-H, et al. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4(1):61.
   PubMedGoogle Scholar
• Amiri-Kordestani L, Basseville A, Kurdziel K, et al. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat. 2012;15(1–2):50–61.
   PubMed Web of Science ®Google Scholar
• Sinués B, Fanlo A, Bernal ML, et al. MDR-1 C3435T genetic polymorphism and tobacco-related lung cancer. Oncology. 2003;64(2):183–185.
   PubMed Web of Science ®Google Scholar
• Barrand MA, Rhodes T, Center MS, et al. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer. 1993;29a(3):408–415.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668.
   PubMed Web of Science ®Google Scholar
• Massarelli E, Papadimitrakopoulou V, Welsh J, et al. Immunotherapy in lung cancer. Transl Lung Cancer Res. 2014;3(1):53–63.
   PubMedGoogle Scholar
• Batchu RB, Gruzdyn O, Potti RB, et al. MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine. JAMA Surg. 2014;149(5):451–457.
   PubMed Web of Science ®Google Scholar
• Palmer M, Parker J, Modi S, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer. 2001;3(1):49–57. discussion 58.
   PubMedGoogle Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of Anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/bacille calmette-guerin in responding patients with limited-disease small-cell lung cancer (European organisation for research and treatment of cancer 08971-08971B; silva study). J Clin Oncol. 2005;23(28):6854–6864.
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimum ab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†. Ann Oncol. 2013;24(1):75–83.
   PubMed Web of Science ®Google Scholar
• Rexer H. Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO. Urologe A. 2015;54(10):1443–1445.
   PubMedGoogle Scholar
• Guo H, Li L, Cui J. Advances and challenges in immunotherapy of small cell lung cancer. Chin J Cancer Res. 2020;32(1):115–128.
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama. 2014;311(19):1998–2006.
   PubMed Web of Science ®Google Scholar
• Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637–658.
   PubMed Web of Science ®Google Scholar
• Planchard D. Identification of driver mutations in lung cancer: first step in personalized cancer. Target Oncol. 2013;8(1):3–14.
   PubMed Web of Science ®Google Scholar
• Patel JN, Ersek JL, Kim ES. Lung cancer biomarkers, targeted therapies and clinical assays. Transl Lung Cancer Res. 2015;4(5):503–514.
   PubMedGoogle Scholar
• Pazarentzos E, Bivona TG. Adaptive stress signaling in targeted cancer therapy resistance. Oncogene. 2015;34(45):5599–5606.
   PubMed Web of Science ®Google Scholar
• Groenendijk FH, Bernards R. Drug resistance to targeted therapies: déjà vu all over again. Mol Oncol. 2014;8(6):1067–1083.
   PubMed Web of Science ®Google Scholar
• Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25(12):563–570.
   PubMed Web of Science ®Google Scholar
• Garrastazu Pereira G, Lawson AJ, Buttini F, et al. Loco-regional administration of nanomedicines for the treatment of lung cancer. Drug Deliv. 2016;23(8):2881–2896.
   PubMed Web of Science ®Google Scholar
• Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev. 2006;58(9):1009–1029.
   PubMed Web of Science ®Google Scholar
• Cryan S-A. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 2005;7(1):E20–E41.
   PubMed Web of Science ®Google Scholar
• Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol. 1998;85(2):379–385.
   PubMed Web of Science ®Google Scholar
• Mansour HM, Rhee Y-S, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;4:299–319.
   PubMed Web of Science ®Google Scholar
• Thomas RJ. Particle size and pathogenicity in the respiratory tract. Virulence. 2013;4(8):847–858.
   PubMed Web of Science ®Google Scholar
• Shen AM, Minko T. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. J Control Release. 2020;326:222–244.
   PubMed Web of Science ®Google Scholar
• Newman SP. Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases. Adv Drug Deliv Rev. 2018;133:5–18.
   PubMed Web of Science ®Google Scholar
• Videira MA, Llop J, Sousa C, et al. Pulmonary administration: Strengthening the value of therapeutic proximity. Front Med (Lausanne). 2020;7:50.
   PubMedGoogle Scholar
• Minamino T, Komuro I. Regeneration of the endothelium as a novel therapeutic strategy for acute lung injury. J Clin Invest. 2006;116(9):2316–2319.
   PubMed Web of Science ®Google Scholar
• Kashima J, Kitadai R, Okuma Y. Molecular and morphological profiling of lung cancer: A foundation for “next-generation”. Pathol Oncolo Cancers (Basel). 2019;11(5):599.
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4(3):e10143–e10143.
   PubMed Web of Science ®Google Scholar
• Kim I, Byeon HJ, Kim TH, et al. Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer. Biomaterials. 2013;34(27):6444–6453.
   PubMed Web of Science ®Google Scholar
• Gharse S, Fiegel J. Large porous hollow particles: Lightweight champions of pulmonary drug delivery. Curr Pharm Des. 2016;22(17):2463–2469.
   PubMed Web of Science ®Google Scholar
• Smirnova I, Suttiruengwong S, Seiler M, et al. Dissolution rate enhancement by adsorption of poorly soluble drugs on hydrophilic silica aerogels. Pharm Dev Technol. 2004;9(4):443–452.
   PubMed Web of Science ®Google Scholar
• Dubinin MM. The potential theory of adsorption of gases and vapors for adsorbents with energetically nonuniform surfaces. Chem Rev. 1960;60(2):235–241.
   Web of Science ®Google Scholar
• Kaneko K. Determination of pore size and pore size distribution: 1. Adsorbents and catalysts. J Membr Sci. 1994;96(1):59–89.
   Web of Science ®Google Scholar
• Arruebo M. Drug delivery from structured porous inorganic materials. WIREs Nanomed Nanobiotechnol. 2012;4(1):16–30.
   Google Scholar
• Su H, Tian Q, Hurd Price C-A, et al. Nanoporous core@shell particles: Design, preparation, applications in bioadsorption and biocatalysis. Nano Today. 2020;31:100834.
   Web of Science ®Google Scholar
• Vinu A, Streb C, Murugesan V, et al. Adsorption of cytochrome c on new mesoporous carbon molecular sieves. J Phys Chem B. 2003;107(33):8297–8299.
   Web of Science ®Google Scholar
• Vinu A, Hartmann M. Adsorption of cytochrome c on MCM-41 and SBA-15: influence of pH. Stud Surf Sci Catal. 2004;154:2987–2994.
   Google Scholar
• Vinu A, Murugesan V, Hartmann M. Adsorption of lysozyme over mesoporous molecular sieves MCM-41 and SBA-15: influence of pH and aluminum incorporation. J Phys Chem B. 2004;108(22):7323–7330.
   Web of Science ®Google Scholar
• Vinu A, Murugesan V, Tangermann O, et al. Adsorption of cytochrome c on mesoporous molecular sieves: influence of pH, pore diameter, and aluminum incorporation. Chem Mater. 2004;16(16):3056–3065.
   Web of Science ®Google Scholar
• Hartmann M, Vinu A, Chandrasekar G. Adsorption of vitamin E on mesoporous carbon molecular sieves. Chem Mater. 2005;17(4):829–833.
   Web of Science ®Google Scholar
• Vinu A, Miyahara M, Ariga K. Biomaterial immobilization in nanoporous carbon molecular sieves: Influence of solution pH, pore volume, and pore diameter. J Phys Chem B. 2005;109(13):6436–6441.
   PubMed Web of Science ®Google Scholar
• Vinu A, Miyahara M, Sivamurugan V, et al. Large pore cage type mesoporous carbon, carbon nanocage: a superior adsorbent for biomaterials. J Mater Chem. 2005;15(48):5122–5127.
   Web of Science ®Google Scholar
• Miyahara M, Vinu A, Hossain KZ, et al. Adsorption study of heme proteins on SBA-15 mesoporous silica with pore-filling models. Thin Solid Films. 2006;499(1–2):13–18.
   Web of Science ®Google Scholar
• Vinu A, Hossain KZ, Kumar GS, et al. Adsorption of L-histidine over mesoporous carbon molecular sieves. Carbon. 2006;44(3):530–536.
   Web of Science ®Google Scholar
• Barbara S. Effects of STM 434 alone or in combination with liposomal doxorubicin in patients with ovarian cancer or other advanced solid tumors. in: U.S.F. Resources (Ed.) clinicalTrials.gov, U.S; 2017.
   Google Scholar
• P. S.p.A, L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours, in: U.S.N.L.o. Medicine (Ed.) clinical Trials, U.S, 28/08/2019.
   Google Scholar
• Pfizer. A study of avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum resistant/refractory ovarian cancer (JAVELIN ovarian 200). NCT02580058. In: Trials C, editor. US. National Library of Medicine. USA; 2015.
   Google Scholar
• C. Trial.gov. Doxil topotecan doublet cancer study. Medicine USNLO, Ed. U.S. National library of Medicine, USA: 2005.
   Google Scholar
• Otterson GA, Villalona-Calero MA, Grainger A, et al. Results of a phase I study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer. J clin oncol. 2005;23(16_suppl):7231.
   PubMedGoogle Scholar
• Otterson GA, Villalona-Calero MA, Hicks W, et al. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(8):2466–2473.
   PubMed Web of Science ®Google Scholar
• Plummer R, Wilson R, Calvert H, et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer. 2011;104:593–598.
   PubMed Web of Science ®Google Scholar
• I. Incorporated, Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung, in: c. Trials (Ed.) U.S, 1/08/2017.
   Google Scholar
• Natale R, Socinski M, Hart L, et al. Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with stage III/IV non-small cell lung cancer. Eur J Cancer. 2014;14(6):19.
   Web of Science ®Google Scholar
• Hirsh V. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2014;14(2):129–141.
   PubMed Web of Science ®Google Scholar
• Gill KK, Nazzal S, Kaddoumi A. Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm. 2011;79(2):276–284.
   PubMed Web of Science ®Google Scholar
• Nakashima K, Akamatsu H, Murakami H, et al. Carboplatin plus nab-paclitaxel in performance status 2 patients with advanced non-small-cell lung cancer. Anticancer Res. 2019;39(3):1463–1468.
   PubMed Web of Science ®Google Scholar
• Corp MSD, A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407), in: c. trials (Ed.) 30/09/2020.
   Google Scholar
• Salgia R, Kulkarni P, Gill PS. EphB4: a promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer. 2018;1869(2):128–137.
   PubMed Web of Science ®Google Scholar
• Lv W-Z, Lin Z, Wang S-Y, et al. Phase II study of a bi-weekly chemotherapy regimen of combined liposomal paclitaxel and nedaplatin for the treatment of advanced squamous cell lung cancer. Transl Oncol. 2019;12(4):656–660.
   PubMed Web of Science ®Google Scholar
• R.M.N.F. Trust, Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma (N3), in: c. trials (Ed.).
   Google Scholar
• Roche H-L, A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130), in: c. trials (Ed.) 4/08/20.
   Google Scholar
• U.S.N.L.o. Medicine, Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung, in: U.o.N. Mexico (Ed.) U.S, 2006.
   Google Scholar
• I. Spectrum Pharmaceuticals, Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors, in: c. trials (Ed.) U.S, 2020.
   Google Scholar
• Godugu C, Patel AR, Doddapaneni R, et al. Inhalation delivery of telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J Control Release. 2013;172(1):86–95.
   PubMed Web of Science ®Google Scholar
• Jiao K, Flynn KT, Kohli P. Synthesis, characterization, and applications of nanoporous materials for sensing and separation. In: Aliofkhazraei M, editor. Handbook of nanoparticles. Cham: Springer International Publishing; 2016. p. 429–454.
   Google Scholar
• Benzigar MR, Talapaneni SN, Joseph S, et al. Recent advances in functionalized micro and mesoporous carbon materials: synthesis and applications. Chem Soc Rev. 2018;47(8):2680–2721.
   PubMed Web of Science ®Google Scholar
• Wu S-H, Mou C-Y, Lin H-P. Synthesis of mesoporous silica nanoparticles. Chem Soc Rev. 2013;42(9):3862–3875.
   PubMed Web of Science ®Google Scholar
• Trewyn BG, Slowing II, Giri S, et al. Synthesis and functionalization of a mesoporous silica nanoparticle based on the Sol–Gel Process And Applications In Controlled Release. Acc Chem Res. 2007;40(9):846–853.
   PubMed Web of Science ®Google Scholar
• Stöber W, Fink A, Bohn E. Controlled growth of monodisperse silica spheres in the micron size range. J Colloid Interface Sci. 1968;26(1):62–69.
   Web of Science ®Google Scholar
• Faustova ZV, Slizhov YG. Effect of solution pH on the surface morphology of sol–gel derived silica gel. Inorg Mater. 2017;53(3):287–291.
   Web of Science ®Google Scholar
• Ariga K, Ji QM, Hill JP, et al. Coupling of soft technology (layer-by-layer assembly) with hard materials (mesoporous solids) to give hierarchic functional structures. Soft Matter. 2009;5(19):3562–3571.
   Web of Science ®Google Scholar
• Lin H-P, Mou C-Y. Structural and morphological control of cationic surfactant-templated mesoporous Silica. Acc Chem Res. 2002;35(11):927–935.
   PubMed Web of Science ®Google Scholar
• Bastakoti BP, Ishihara S, Leo S-Y, Ariga K, Wu KCW, Yamauch, Y, et al. Polymeric Micelle Assembly for Preparation of Large-Sized Mesoporous Metal Oxides with Various Compositions. Langmuir. 2014;30(2):651–659.
   PubMed Web of Science ®Google Scholar
• Zhou X, Cheng X, Feng W, et al. Synthesis of hollow mesoporous silica nanoparticles with tunable shell thickness and pore size using amphiphilic block copolymers as core templates. Dalton Trans. 2014;43(31):11834–11842.
   PubMed Web of Science ®Google Scholar
• Lin Y-S, Wu S-H, Tseng C-T, et al. Synthesis of hollow silica nanospheres with a microemulsion as the template. Chem Comm. 2009;24:3542–3544.
   Google Scholar
• Cauvel A, Brunel D, Di Renzo F, et al. Hydrophobic and hydrophilic behavior of Micelle-Templated mesoporous Silica. Langmuir. 1997;13(10):2773–2778.
   Web of Science ®Google Scholar
• Hao N, Chen X, Jayawardana KW, et al. Shape control of mesoporous silica nanomaterials templated with dual cationic surfactants and their antibacterial activities. Biomater Sci. 2016;4(1):87–91.
   PubMed Web of Science ®Google Scholar
• Barczak M. Template removal from mesoporous silicas using different methods as a tool for adjusting their properties. New J Chem. 2018;42(6):4182–4191.
   Web of Science ®Google Scholar
• Schüth F. Endo- and exotemplating to create High-Surface-Area inorganic materials. Angew Chem. 2003;42(31):3604–3622.
   Google Scholar
• Sasidharan M, Zenibana H, Nandi M, et al. Synthesis of mesoporous hollow silica nanospheres using polymeric micelles as template and their application as a drug-delivery carrier. Dalton Trans. 2013;42(37):13381–13389.
   PubMed Web of Science ®Google Scholar
• Narayan R, Nayak UY, Raichur AM, et al. Mesoporous Silica nanoparticles: A comprehensive review on synthesis and recent advances. Pharmaceutics. 2018;10(3):118.
   PubMed Web of Science ®Google Scholar
• Vinu A, Terrones M, Golberg D, et al. Synthesis of mesoporous BN and BCN exhibiting large surface areas via templating methods. Chem Mater. 2005;17(24):5887–5890.
   Web of Science ®Google Scholar
• Vinu A. Two-dimensional hexagonally-ordered mesoporous carbon nitrides with tunable pore diameter, surface area and nitrogen content. Adv Funct Mater. 2008;18(5):816–827.
   Web of Science ®Google Scholar
• Lakhi KS, Park DH, Al-Bahily K, et al. Mesoporous carbon nitrides: synthesis, functionalization, and applications. Chem Soc Rev. 2017;46(1):72–101.
   PubMed Web of Science ®Google Scholar
• Mane GP, Talapaneni SN, Lakhi KS, et al. Highly ordered nitrogen-rich mesoporous carbon nitrides and their superior performance for sensing and photocatalytic hydrogen generation. Angew Chem Int Edit. 2017;56(29):8481–8485.
   PubMed Web of Science ®Google Scholar
• Kesavan T, Partheeban T, Vivekanantha M, et al. Design of P-doped mesoporous carbon nitrides as high-performance anode materials for li-ion battery. Acs Appl Mater Inter. 2020;12(21):24007–24018.
   PubMed Web of Science ®Google Scholar
• Talapaneni SN, Singh G, Kim IY, et al. Nanostructured carbon nitrides for CO2 Capture and conversion. Adv Mater. 2020;32(18):1904635.
   PubMed Web of Science ®Google Scholar
• Baskar AV, Benzigar MR, Talapaneni SN, et al. Self-assembled fullerene nanostructures: Synthesis and applications. Adv Funct Mater. 2021;32(6):2106924.
   Web of Science ®Google Scholar
• Benzigar MR, Joseph S, Baskar AV, et al. Ordered mesoporous C-70 with highly crystalline pore walls for energy applications. Adv Funct Mater. 2018;28(35):1803701.
   Web of Science ®Google Scholar
• Benzigar MR, Joseph S, Ilbeygi H, et al. Highly crystalline mesoporous C-60 with ordered pores: A class of nanomaterials for energy applications. Angew Chem Int Edit. 2018;57(2):569–573.
   PubMed Web of Science ®Google Scholar
• Suryavanshi U, Balasubramanian VV, Lakhi KS, et al. Mesoporous BN and BCN nanocages with high surface area and spherical morphology. Phys Chem Chem Phys. 2014;16(43):23554–23557.
   PubMed Web of Science ®Google Scholar
• Mane GP, Talapaneni SN, Lakhi KS, et al. Highly ordered nitrogen-rich mesoporous carbon nitrides and their superior performance for sensing and photocatalytic hydrogen generation. Angew Chem. 2017;56(29):8481–8485.
   Google Scholar
• Yanwei H. Synthesis of SiO2 nanoparticles by chemical precipitation. CIESC J. 2016;67(S1):379–383.
   Google Scholar
• Sun Y, Chen Y, Ma X, et al. Mitochondria-targeted hydroxyapatite nanoparticles for selective growth inhibition of lung cancer in vitro and in vivo. ACS Appl Mater Interfaces. 2016;8(39):25680–25690.
   PubMed Web of Science ®Google Scholar
• Chuang L, Jin S, Guan W, Tsang C.-K, Chu W.-K, Lau W.K, Liang C. Chemical Precipitation Method for the Synthesis of Nb2O5 Modified Bulk Nickel Catalysts with High Specific Surface Area. J Visualized Exper. 2018; 132:56987.
   Google Scholar
• Koźlecki T, Polowczyk I, Bastrzyk A, et al. Improved synthesis of nanosized silica in water-in-oil microemulsions. J Nanoparticles. 2016;2016:8203260.
   Google Scholar
• Malik MA, Wani MY, Hashim MA. Microemulsion method: a novel route to synthesize organic and inorganic nanomaterials: 1st nano update. Arabian J Chem. 2012;5(4):397–417.
   Web of Science ®Google Scholar
• Lv -P-P, Wei W, Yue H, et al. Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration. Biomacromolecules. 2011;12(12):4230–4239.
   PubMed Web of Science ®Google Scholar
• Bumajdad A, Zaki MI, Eastoe J, et al. Microemulsion-Based synthesis of CeO2 powders with high surface area and high-temperature stabilities. Langmuir. 2004;20(25):11223–11233.
   PubMed Web of Science ®Google Scholar
• Finnie KS, Bartlett JR, Barbé CJA, et al. Formation of Silica nanoparticles in microemulsions. Langmuir. 2007;23(6):3017–3024.
   PubMed Web of Science ®Google Scholar
• Singh G, Lakhi KS, Sil S, et al. Biomass derived porous carbon for CO2 capture. Carbon. 2019;148:164–186.
   Web of Science ®Google Scholar
• Godbole R, Godbole VP, Alegaonkar PS, et al. Effect of film thickness on gas sensing properties of sprayed WO3 thin films. New J Chem. 2017;41(20):11807–11816.
   Web of Science ®Google Scholar
• Yuan Y, Liu C, Zhang Y, et al. Sol–gel auto-combustion synthesis of hydroxyapatite nanotubes array in porous alumina template. Mater Chem Phys. 2008;112(1):275–280.
   Web of Science ®Google Scholar
• Salem S, Salem A, Parni MH, et al. Facile and rapid auto-combustion synthesis of nano-porous γ-Al&#x003C2O3 by application of hexamethylenetetramine in fuel composition. J Phys Chem Solids. 2018;117:86.
   Web of Science ®Google Scholar
• Vinu A, Dedecek J, Murugesan V, et al. Synthesis and characterization of CoSBA-1 cubic mesoporous molecular sieves. Chem Mater. 2002;14(6):2433-+.
   Web of Science ®Google Scholar
• Karthik M, Tripathi AK, Gupta NM, et al. Characterization of Co,Al-MCM-41 and its activity in the t-butylation of phenol using isobutanol. Appl Catal A Gen. 2004;268(1–2):139–149.
   Web of Science ®Google Scholar
• Vinu A, Krithiga T, Murugesan V, et al. Direct synthesis of novel FeSBA-1 cubic mesoporous catalyst and its high activity in the tert-butylation of phenol. Adv Mater. 2004;16(20):1817-+.
   Web of Science ®Google Scholar
• Vinu A, Nandhini KU, Murugesan V, et al. Mesoporous FeAlMCM-41: an improved catalyst for the vapor phase tert-butylation of phenol. Appl Catal A Gen. 2004;265(1):1–10.
   Web of Science ®Google Scholar
• Vinu A, Devassy BM, Halligudi SB, et al. Highly active and selective AlSBA-15 catalysts for the vapor phase tert-butylation of phenol. Appl Catal A Gen. 2005;281(1–2):207–213.
   Web of Science ®Google Scholar
• Vinu A, Sawant DP, Ariga K, et al. Direct synthesis of well-ordered and unusually reactive FeSBA-15 mesoporous molecular sieves. Chem Mater. 2005;17(21):5339–5345.
   Web of Science ®Google Scholar
• Vinu A, Srinivasu P, Miyahara M, et al. Preparation and catalytic performances of ultralarge-pore TiSBA-15 mesoporous molecular sieves with very high Ti content. J Phys Chem B. 2006;110(2):801–806.
   PubMed Web of Science ®Google Scholar
• Srinivasu P, Alam S, Balasubramanian VV, et al. Novel three dimensional cubic Fm3m mesoporous aluminosilicates with tailored cage type pore structure and high aluminum content. Adv Funct Mater. 2008;18(4):640–651.
   Web of Science ®Google Scholar
• Srinivasu P, Anand C, Alam S, et al. Direct synthesis and the morphological control of highly ordered two-dimensional P6mm mesoporous niobium silicates with high niobium content. J Phys Chem C. 2008;112(27):10130–10140.
   Web of Science ®Google Scholar
• Srinivasu P, Vinu A. Three-dimensional mesoporous gallosilicate with Pm3n symmetry and its unusual catalytic performances. Chem Eur J. 2008;14(12):3553–3561.
   PubMed Web of Science ®Google Scholar
• Vinu A, Srinivasu P, Balasubramanian VV, et al. Three-dimensional mesoporous TiKIT-6 with Ia3d symmetry synthesized at low acid concentration and its catalytic performances. Chem Lett. 2008;37(10):1016–1017.
   Web of Science ®Google Scholar
• Dhand C, Prabhakaran MP, Beuerman RW, et al. Role of size of drug delivery carriers for pulmonary and intravenous administration with emphasis on cancer therapeutics and lung-targeted drug delivery. RSC Adv. 2014;4(62):32673–32689.
   Web of Science ®Google Scholar
• Shang L, Nienhaus K, Nienhaus GU. Engineered nanoparticles interacting with cells: size matters. J Nanobiotechnology. 2014;12(1):5.
   PubMed Web of Science ®Google Scholar
• Olivares-Morales A, Hatley OJ, Turner D, et al. The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data. Pharm Res. 2014;31(3):720–730.
   PubMed Web of Science ®Google Scholar
• Maurya P, Singh S, Saraf SA. Targeting chronic inflammatory lung diseases using advanced drug delivery systems. London: Elsevier. 2020;.
   Google Scholar
• Huang Z, Kłodzińska SN, Wan F, et al. Nanoparticle-mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections. Drug Deliv Transl Res. 2021;11(4):1634–1654.
   Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588–599.
   PubMed Web of Science ®Google Scholar
• Yazdi IK, Ziemys A, Evangelopoulos M, et al. Physicochemical properties affect the synthesis, controlled delivery, degradation and pharmacokinetics of inorganic nanoporous materials. Nanomedicine. 2015;10(19):3057–3075.
   PubMed Web of Science ®Google Scholar
• Sevimli F, Yılmaz A. Surface functionalization of SBA-15 particles for amoxicillin delivery. Microporous Mesoporous Mater. 2012;158:281–291.
   Web of Science ®Google Scholar
• Huang X, Li L, Liu T, et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano. 2011;5(7):5390–5399.
   PubMed Web of Science ®Google Scholar
• Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24(12):1504–1534.
   PubMed Web of Science ®Google Scholar
• Li X, Xue M, Raabe OG, et al. Aerosol droplet delivery of mesoporous silica nanoparticles: a strategy for respiratory-based therapeutics. Nanomedicine. 2015;11(6):1377–1385.
   PubMed Web of Science ®Google Scholar
• Shahbazi M-A, Herranz B, Santos HA. Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter. 2012;2(4):296–312.
   PubMedGoogle Scholar
• Issa AA, Luyt AS. Kinetics of alkoxysilanes and organoalkoxysilanes polymerization: A review. Polym (Basel). 2019;11(3): 537.
   PubMed Web of Science ®Google Scholar
• Christy A. The nature of silanol groups on the surfaces of silica, modified silica and some silica based materials. Adv Mater Res. 2014;998-999:3–10.
   Google Scholar
• Vinu A, Hossain K, Ariga K. Recent advances in functionalization of mesoporous silica. J Nanosci Nanotechnol. 2005;5:347–371.
   PubMed Web of Science ®Google Scholar
• Slowing I, Trewyn BG, Lin VSY. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells. J Am Chem Soc. 2006;128(46):14792–14793.
   PubMed Web of Science ®Google Scholar
• Graf C, Gao Q, Schütz I, et al. Surface functionalization of silica nanoparticles supports colloidal stability in physiological media and facilitates internalization in cells. Langmuir. 2012;28(20):7598–7613.
   PubMed Web of Science ®Google Scholar
• Bharti C, Nagaich U, Pal AK, et al. Mesoporous silica nanoparticles in target drug delivery system: a review. Int J Pharm Investig. 2015;5(3):124–133.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Quan G, Wu Q, et al. Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm Sin B. 2018;8(2):165–177.
   PubMed Web of Science ®Google Scholar
• Ezzati N, Mahjoub AR, Abolhosseini Shahrnoy A, et al. Amino Acid-functionalized hollow mesoporous silica nanospheres as efficient biocompatible drug carriers for anticancer applications. Int J Pharm. 2019;572:118709.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Wu C, Jiang J, et al. Lipid-coated hollow mesoporous silica nanospheres for co-delivery of doxorubicin and paclitaxel: preparation, sustained release, cellular uptake and pharmacokinetics. Mater Sci Eng C-Mater Biol Appl. 2017;71:835–843.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang H-Y, Yang L, et al. Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance. Sci Rep. 2016;6:25468.
   Google Scholar
• Park SS, Jung MH, Lee Y-S, et al. Functionalised mesoporous silica nanoparticles with excellent cytotoxicity against various cancer cells for pH-responsive and controlled drug delivery. Mater Des. 2019;184:108187.
   Web of Science ®Google Scholar
• Vivero-Escoto JL, Elnagheeb M. Mesoporous silica nanoparticles loaded with cisplatin and phthalocyanine for combination chemotherapy and photodynamic therapy in vitro. Nanomaterials (Basel). 2015;5(4):2302–2316.
   PubMedGoogle Scholar
• Munaweera I, Shi Y, Koneru B, et al. Nitric oxide- and cisplatin-releasing silica nanoparticles for use against non-small cell lung cancer. J Inorg Biochem. 2015;153:23–31.
   PubMed Web of Science ®Google Scholar
• Su W, Wei T, Lu M, et al. Treatment of metastatic lung cancer via inhalation administration of curcumin composite particles based on mesoporous silica. Eur J Pharm Sci. 2019;134:246–255.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu Y, Lee RJ, et al. Nano encapsulated curcumin: and its potential for biomedical applications. Int J Nanomedicine. 2020;15:3099–3120.
   PubMed Web of Science ®Google Scholar
• Hong SH, Choi Y. Mesoporous silica-based nanoplatforms for the delivery of photodynamic therapy agents. J Pharm Invest. 2018;48(1):3–17.
   PubMedGoogle Scholar
• Sanoj Rejinold N, Choi G, Choy J-H. Recent trends in nano photo-chemo therapy approaches and future scopes. Coord Chem Rev. 2020;411:213252.
   Web of Science ®Google Scholar
• Ellahioui Y, Patra M, Mari C, et al. Mesoporous silica nanoparticles functionalised with a photoactive ruthenium(ii) complex: exploring the formulation of a metal-based photodynamic therapy photosensitiser. Dalton Trans. 2019;48(18):5940–5951.
   PubMed Web of Science ®Google Scholar
• Wang L-S, Wu L-C, Lu S-Y, et al. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: Improved water suspensibility and decreased nonspecific protein binding. ACS Nano. 2010;4(8):4371–4379.
   PubMed Web of Science ®Google Scholar
• de Souza Oliveira RC, Corrêa RJ, Teixeira RSP, et al. Silica nanoparticles doped with anthraquinone for lung cancer phototherapy. J Photochem Photobiol B Biol. 2016;165:1–9.
   PubMed Web of Science ®Google Scholar
• Hemmer E, Benayas A, Légaré F, et al. Exploiting the biological windows: current perspectives on fluorescent bioprobes emitting above 1000 nm. Nanoscale Horiz. 2016;1(3):168–184.
   PubMed Web of Science ®Google Scholar
• Soni AK, Joshi R, Singh BP, et al. Near-Infrared- and magnetic-field-responsive NaYF4:Er3+/Yb3+@SiO2@AuNP@Fe3O4 nanocomposites for hyperthermia applications induced by fluorescence resonance energy transfer and surface plasmon absorption. ACS Appl Nano Mater. 2019;2(11):7350–7361.
   Web of Science ®Google Scholar
• Joshi R, Perala RS, Shelar SB, et al. Super bright red upconversion in NaErF4:0.5%Tm@NaYF4:20%Yb nanoparticles for anti-counterfeit and bioimaging applications. ACS Appl Mater Interfaces. 2021;13(2):3481–3490.
   PubMed Web of Science ®Google Scholar
• Chen Y, Gu H, Zhang DS-Z, et al. Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier. Biomaterials. 2014;35(38):10058–10069.
   PubMed Web of Science ®Google Scholar
• Dilnawaz F, Sahoo SK. Augmented anticancer efficacy by si-RNA complexed drug-loaded mesoporous silica nanoparticles in lung cancer therapy. ACS Appl Nano Mater. 2018;1(2):730–740.
   Web of Science ®Google Scholar
• Li W, Guo Z, Zheng K, Ma K, Cui C, Wang L, Yuan Y, Tang Y. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis. International Journal of Pharmaceutics. 2017;534(1–2):71–80.
   PubMed Web of Science ®Google Scholar
• Liu Y, Dai R, Wei Q, et al. Dual-Functionalized janus mesoporous silica nanoparticles with active targeting and charge reversal for synergistic tumor-targeting therapy. ACS Appl Mater Interfaces. 2019;11(47):44582–44592.
   PubMed Web of Science ®Google Scholar
• Rong JM, Li PC, Ge YK, et al. Histone H2A-peptide-hybrided upconversion mesoporous silica nanoparticles for bortezomib/p53 delivery and apoptosis induction. Colloid Surf B-Biointerfaces. 2020;186:11.
   Web of Science ®Google Scholar
• van Rijt SH, Bölükbas DA, Argyo C, et al. Protease- Mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors. ACS Nano. 2015;9(3):2377–2389.
   PubMed Web of Science ®Google Scholar
• Sundarraj S, Thangam R, Sujitha MV, et al. Ligand- conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy. Toxicol Appl Pharmacol. 2014;275(3):232–243.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen H, Zeng D, et al. Core/Shell structured hollow mesoporous nanocapsules: A potential platform for simultaneous cell imaging and anticancer drug delivery. ACS Nano. 2010;4(10):6001–6013.
   PubMed Web of Science ®Google Scholar
• Alvarez-Berríos MP, Sosa-Cintron N, Rodriguez-Lugo M, et al. Hybrid nanomaterials based on iron oxide nanoparticles and mesoporous silica nanoparticles: Overcoming challenges in current cancer treatments. J Chem. 2016;2016:2672740.
   Web of Science ®Google Scholar
• Rosenholm JM, Meinander A, Peuhu E, et al. Targeting of porous hybrid silica nanoparticles to cancer cells. ACS Nano. 2009;3(1):197–206.
   PubMed Web of Science ®Google Scholar
• Marini M, Pourabbas B, Pilati F, et al. Functionally modified core-shell silica nanoparticles by one-pot synthesis. Colloids Surf A. 2008;317(1):473–481.
   Google Scholar
• Atkin R, Bradley M, Vincent B. Core–shell particles having silica cores and pH-responsive poly(vinylpyridine) shells. Soft Matter. 2005;1(2):160–165.
   PubMed Web of Science ®Google Scholar
• Chen X, Liu Z, Parker SG, et al. Light-Induced hydrogel based on tumor-targeting mesoporous silica nanoparticles as a theranostic platform for sustained cancer treatment. ACS Appl Mater Interfaces. 2016;8(25):15857–15863.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang K, Zhao J, et al. Multifunctional mesoporous silica-coated graphene nanosheet used for chemo-photothermal synergistic targeted therapy of glioma. J Am Chem Soc. 2013;135(12):4799–4804.
   PubMed Web of Science ®Google Scholar
• Wang H, Xu YD, Zhou X. Docetaxel-Loaded chitosan microspheres as a lung targeted drug delivery system: in vitro and in vivo evaluation. Int J Mol Sci. 2014;15(3):3519–3532.
   PubMed Web of Science ®Google Scholar
• Han L, Zhang Y, Zhang Y, et al. A magnetic polypyrrole/iron oxide core/gold shell nanocomposite for multimodal imaging and photothermal cancer therapy. Talanta. 2017;171:32–38.
   PubMed Web of Science ®Google Scholar
• Mowat P, Mignot A, Rima W, et al. In vitro radiosensitizing effects of ultrasmall gadolinium based particles on tumour cells. J Nanosci Nanotechnol. 2011;11(9):7833–7839.
   PubMed Web of Science ®Google Scholar
• Rima W, Sancey L, Aloy MT, et al. Internalization pathways into cancer cells of gadolinium-based radiosensitizing nanoparticles. Biomaterials. 2013;34(1):181–195.
   PubMed Web of Science ®Google Scholar
• Hao C, Wu X, Sun M, et al. Chiral core-shell upconversion nanoparticle@MOF nanoassemblies for quantification and bioimaging of reactive oxygen species in vivo. J Am Chem Soc. 2019;141(49):19373–19378.
   PubMed Web of Science ®Google Scholar
• Ansari AA, Siddiqui MA, Khan A, et al. Luminescent surface-functionalized mesoporous core-shell nanospheres and their cytotoxicity evaluation. Colloids Surf A Physicochem Eng Asp. 2019;573:146–156.
   Web of Science ®Google Scholar
• Bi X, Zhang H, Dou L. Layered double hydroxide-based nanocarriers for drug delivery. Pharmaceutics. 2014;6(2):298–332.
   PubMedGoogle Scholar
• Choi S-J, Oh J-M, Choy J-H. Anticancer drug-layered hydroxide nanohybrids as potent cancer chemotherapy agents. J Phys Chem Solids. 2008;69(5):1528–1532.
   Web of Science ®Google Scholar
• Zhu R, Wang Q, Zhu Y, et al. pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer. Acta Biomater. 2016;29:320–332.
   PubMed Web of Science ®Google Scholar
• Ma K, Li Y, Wang Z, et al. Core–Shell gold nanorod@layered double hydroxide nanomaterial with highly efficient photothermal conversion and its application in antibacterial and tumor therapy. ACS Appl Mater Interfaces. 2019;11(33):29630–29640.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhu R, Wang M, et al. Anti-Metastatic and anti-angiogenic activities of Core-Shell SiO(2)@LDH loaded with etoposide in Non-small cell lung cancer. Adv Sci (Weinh). 2016;3(11):1600229.
   PubMedGoogle Scholar
• Ma R, Wang Z, Yan L, et al. Novel Pt-loaded layered double hydroxide nanoparticles for efficient and cancer-cell specific delivery of a cisplatin prodrug. J Mat Chem B. 2014;2(30):4868–4875.
   PubMed Web of Science ®Google Scholar
• Zhu R, Wang Q, Zhu Y, et al. PH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer. Acta Biomater. 2015;29:320–332.
   Web of Science ®Google Scholar
• Qin Z, Joo J, Gu L, et al. Size control of porous silicon nanoparticles by electrochemical perforation etching. Part Part Syst Charact. 2014;31(2):252–256.
   Web of Science ®Google Scholar
• Yang X, Xi F, Chen X, et al. Porous silicon fabrication and surface cracking behavior research based on anodic electrochemical etching. Fuel Cells. 2021;21(1):52–57.
   Web of Science ®Google Scholar
• Nissinen T, Näkki S, Laakso H, et al. Tailored dual PEGylation of inorganic porous nanocarriers for extremely long blood circulation in vivo. ACS Appl Mater Interfaces. 2016;8(48):32723–32731.
   PubMed Web of Science ®Google Scholar
• Chen S, Ni B, Huang H, et al. siRNA-loaded PEGylated porous silicon nanoparticles for lung cancer therapy. J Nanopart Res. 2014;16(10):2648.
   Web of Science ®Google Scholar
• Gao Y, Che X, Zheng C, et al. Effect of an albumin-coated mesoporous silicon nanoparticle platform for paclitaxel delivery in human lung cancer cell line A549. J Nanomater. 2016;2016:4086456.
   Web of Science ®Google Scholar
• Kawanabe K, Yamamuro T, Kotani S, et al. Acute nephrotoxicity as an adverse effect after intraperitoneal injection of massive amounts of bioactive ceramic powders in mice and rats. J Biomed Mater Res. 1992;26(2):209–219.
   PubMed Web of Science ®Google Scholar
• Canham LT, Reeves CL, Newey JP, et al. Derivatized mesoporous silicon with dramatically improved stability in simulated human blood plasma. Adv Mater. 1999;11(18):1505–1507.
   Web of Science ®Google Scholar
• Canham LT, Stewart MP, Buriak JM, et al. Derivatized porous silicon mirrors: Implantable optical components with slow resorbability. Phys Status Solidi A. 2000;182(1):521–525.
   Google Scholar
• Anglin EJ, Cheng L, Freeman WR, et al. Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev. 2008;60(11):1266–1277.
   PubMed Web of Science ®Google Scholar
• Flügel E, Ranft A, Haase F, et al. Synthetic routes toward MOF nanomorphologies. J Mater Chem. 2012;22:10119–10133.
   Web of Science ®Google Scholar
• Díaz-García D, Sommerova L, Martisova A, et al. Mesoporous silica nanoparticles functionalized with a dialkoxide diorganotin(IV) compound: In search of more selective systems against cancer cells. Microporous Mesoporous Mater. 2020;300:110154.
   Web of Science ®Google Scholar
• Näkki S, Wang JTW, Wu J, et al. Designed inorganic porous nanovector with controlled release and MRI features for safe administration of doxorubicin. Int J Pharm. 2019;554:327–336.
   PubMedGoogle Scholar
• Li Y, Yun K-H, Lee H, et al. Porous platinum nanoparticles as a high-Z and oxygen generating nanozyme for enhanced radiotherapy in vivo. Biomaterials. 2019;197:12–19.
   PubMed Web of Science ®Google Scholar
• Hadinoto K, Phanapavudhikul P, Kewu Z, et al. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids. Int J Pharm. 2007;333(1–2):187–198.
   PubMed Web of Science ®Google Scholar
• Wang T, Liu Y, Wu C. Effect of paclitaxel-mesoporous silica nanoparticles with a core-shell structure on the human lung cancer cell line A549. Nanoscale Res Lett. 2017;12(1):66.
   PubMedGoogle Scholar
• Wang Y, Huang HY, Yang L, et al. Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance. Sci Rep. 2016;6:25468.
   PubMed Web of Science ®Google Scholar
• Yang B, Shen M, Liu J, et al. Post-Synthetic modification nanoscale metal-organic frameworks for targeted drug delivery in cancer cells. Pharm Res. 2017;34(11):2440–2450.
   PubMed Web of Science ®Google Scholar
• Cheng L, Huang FZ, Cheng LF, et al. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation. Int J Nanomedicine. 2014;9:921–935.
   PubMed Web of Science ®Google Scholar
• Xie RZ, Lian S, Peng HY, et al. Mitochondria and nuclei dual-targeted hollow carbon nanospheres for cancer chemophotodynamic synergistic therapy, Mol. Pharm. 2019;16(5):2235–2248.
   Google Scholar
• Luo Y, Wang X, Du D, et al. Hyaluronic acid-conjugated apoferritin nanocages for lung cancer targeted drug delivery. Biomater Sci. 2015;3(10):1386–1394.
   PubMed Web of Science ®Google Scholar
• Illum L, Jabbal-Gill I, Hinchcliffe M, et al. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev. 2001;51(1):81–96.
   PubMed Web of Science ®Google Scholar
• Meenach SA, Kim YJ, Kauffman KJ, et al. Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery, mol. Pharmaceutics. 2012;9(2):290–298.
   Web of Science ®Google Scholar
• Wersig T, Krombholz R, Janich C, et al. Indomethacin functionalised poly(glycerol adipate) nanospheres as promising candidates for modified drug release. Eur J Pharm Sci. 2018;123:350–361.
   PubMed Web of Science ®Google Scholar
• Zhang YY, Zhang L, Lin XW, et al. Dual-responsive nanosystem for precise molecular subtyping and resistant reversal of EGFR targeted therapy. Chem Eng J. 2019;372:483–495.
   Web of Science ®Google Scholar
• Chen F, Zhang F, Shao D, et al. Bioreducible and traceable Ru(III) prodrug-loaded mesoporous silica nanoparticles for sequentially targeted nonsmall cell lung cancer chemotherapy. Appl Mater Today. 2020;19:100558.
   Web of Science ®Google Scholar
• Sun YJ, Dong WB, Wang HY, et al. Template synthesis of PMAA@chitosan hollow nanorods for docetaxel delivery. Polym Chem. 2013;4(8):2489–2495.
   Web of Science ®Google Scholar
• Xia Y, Chen Y, Hua L, et al. Functionalized selenium nanopartices for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy. Int J Nanomedicine. 2018;13:6929–6939.
   PubMed Web of Science ®Google Scholar
• Su W, Wei T, Lu M, et al. Treatment of metastatic lung cancer via inhalation administration of curcumin composite particles based on mesoporous silica. Eur J Pharm Sci. 2019;134:246–255.
   PubMed Web of Science ®Google Scholar
• Li D, Li L-F, Zhang Z-F, et al. Ultrasound-assisted synthesis of a new nanostructured Ca(II)-MOF as 5-FU delivery system to inhibit human lung cancer cell proliferation, migration, invasion and induce cell apoptosis. J Coord Chem. 2020;73(2):266–281.
   Web of Science ®Google Scholar
• Lv PP, Wei W, Yue H, et al. Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration. Biomacromolecules. 2011;12(12):4230–4239.
   PubMed Web of Science ®Google Scholar
• Sinha B, Mukherjee B, Pattnaik G. Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: in vitro and in vivo study. Nanomedicine. 2013;9(1):94–104.
   PubMed Web of Science ®Google Scholar
• Moro M, Di Paolo D, Milione M, et al. Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. J Control Release. 2019;308:44–56.
   PubMed Web of Science ®Google Scholar
• Chen Y-W, Chen P-J, Hu S-H, et al. NIR-Triggered synergic photo-chemothermal therapy delivered by reduced graphene oxide/carbon/mesoporous silica nanocookies. Adv Funct Mater. 2014;24(4):451–459.
   Web of Science ®Google Scholar
• Nakki S, Wang JTW, Wu JW, et al. Designed inorganic porous nanovector with controlled release and MRI features for safe administration of doxorubicin. Int J Pharm. 2019;554:327–336.
   PubMedGoogle Scholar
• Tamarov K, Xu W, Osminkina L, et al. Temperature responsive porous silicon nanoparticles for cancer therapy - spatiotemporal triggering through infrared and radiofrequency electromagnetic heating. J Control Release. 2016;241:220–228.
   PubMed Web of Science ®Google Scholar
• Yang Y, Huang ZW, Li JY, et al. PLGA Porous microspheres dry powders for codelivery of afatinib-loaded solid lipid nanoparticles and paclitaxel: novel therapy for egfr tyrosine kinase inhibitors resistant nonsmall cell lung cancer. Adv Healthc Mater. 2019;8(23):1900965.
   Web of Science ®Google Scholar
• Kamel NM, Helmy MW, Abdelfattah E-Z, et al. Inhalable dual-targeted hybrid lipid nanocore–protein shell composites for combined delivery of genistein and all-trans retinoic acid to lung cancer cells. ACS Biomater Sci Eng. 2020;6(1):71–87.
   PubMed Web of Science ®Google Scholar
• Sundarraj S, Thangam R, Sujitha MV, et al. Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy. Toxicol Appl Pharmacol. 2014;275(3):232–243.
   PubMed Web of Science ®Google Scholar
• Song Y, Zhou B, Du X, et al. Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC. Biomed Pharmacother. 2020;125:109561.
   PubMed Web of Science ®Google Scholar
• Cheng W, Liang C, Xu L, et al. TPGS-functionalized polydopamine-modified mesoporous silica as drug nanocarriers for enhanced lung cancer chemotherapy against multidrug resistance. Small. 2017;13(29):1700623.
   Web of Science ®Google Scholar
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975–999.
   PubMed Web of Science ®Google Scholar
• James JS. DOXIL approved for KS, AIDS Treat News. 1995:236:6.
   Google Scholar
• Cheng L, Huang F-Z, Cheng L-F, et al. GEII-modified liposomes for non-small cell lung cancer targeting: Preparation, ex vitro and in vivo evaluation. Int J Nanomedicine. 2014;9:921–935.
   PubMed Web of Science ®Google Scholar
• Master AM, Qi Y, Oleinick NL, et al. EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies. Nanomedicine. 2012;8(5):655–664.
   PubMed Web of Science ®Google Scholar
• Lin C, Zhang X, Chen H, et al. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide. Drug Deliv. 2018;25(1):256–266.
   PubMed Web of Science ®Google Scholar
• Song X-L, Ju R-J, Xiao Y, et al. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer. Int J Nanomedicine. 2017;12:7433–7451.
   PubMed Web of Science ®Google Scholar
• Cao H, Dan Z, He X, et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano. 2016;10(8):7738–7748.
   PubMed Web of Science ®Google Scholar
• Lin C, Wong BCK, Chen H, et al. Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy. Sci Rep. 2017;7(1):1097.
   PubMedGoogle Scholar
• Zhu L, Li M, Liu X, et al. Inhalable oridonin-loaded poly(lactic-co-glycolic)acid large porous microparticles for in situ treatment of primary non-small cell lung cancer. Acta Pharm Sin B. 2017;7(1):80–90.
   PubMed Web of Science ®Google Scholar
• Chereddy KK, Vandermeulen G, Préat V. PLGA based drug delivery systems: Promising carriers for wound healing activity. Wound Repair Regen. 2016;24(2):223–236.
   PubMed Web of Science ®Google Scholar
• Pieper S, Langer K, Doxorubicin-loaded PLGA nanoparticles - a systematic evaluation of preparation techniques and parameters, Materials Today: Proceedings 4 (2017) S188–S192. Germany: 7th North Rhine-Westphalian Nano-Conference.
   Google Scholar
• Alipour S, Montaseri H, Tafaghodi M. Inhalable, large porous PLGA microparticles loaded with paclitaxel: preparation, in vitro and in vivo characterization. J Microencapsul. 2015;32(7):661–668.
   PubMed Web of Science ®Google Scholar
• Feng T, Tian H, Xu C, et al. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. Eur J Pharm Biopharm. 2014;88(3):1086–1093.
   PubMed Web of Science ®Google Scholar
• Wang C, Wu D, Yang J, et al. Porous PLGA microparticles to encapsulate doxorubicin and polyethylenimine/miR-34a for inhibiting the proliferation and migration of lung cancer. RSC Adv. 2015;5(99):81445–81448.
   Web of Science ®Google Scholar
• Zhu L, Li M, Liu X, et al. Drug-Loaded PLGA electrospraying porous microspheres for the local therapy of primary lung cancer via pulmonary delivery. ACS Omega. 2017;2(5):2273–2279.
   PubMed Web of Science ®Google Scholar
• Kuriakose AE, Hu W, Nguyen KT, et al. Scaffold-based lung tumor culture on porous PLGA microparticle substrates. PLoS One. 2019;14(5):e0217640–e0217640.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Cheng W, Pan Y, et al. An anticancer agent-loaded PLGA nanomedicine with glutathione-response and targeted delivery for the treatment of lung cancer. J Mat Chem B. 2020;8(4):655–665.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhu J, Bao P, et al. Construction and in vivo/in vitro evaluation of a nanoporous ion-responsive targeted drug delivery system for recombinant human interferon α-2b delivery. Int J Nanomedicine. 2019;14:5339–5353.
   PubMed Web of Science ®Google Scholar
• Wang H, Xu Y, Zhou X. Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: in vitro and in vivo evaluation. Int J Mol Sci. 2014;15(3):3519–3532.
   PubMed Web of Science ®Google Scholar
• Moro M, Di Paolo D, Milione M, et al. Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. J Control Release. 2019;308:44–56.
   PubMed Web of Science ®Google Scholar
• Xu Z, Hu L, Ming J, et al. Self-gated porous organic polymer as drug delivery system for pH stimuli-responsive controlled Quercetin release. Microporous Mesoporous Mater. 2020;303:110259.
   Web of Science ®Google Scholar
• De Souza R, Zahedi P, Allen CJ, et al. Polymeric drug delivery systems for localized cancer chemotherapy. Drug Deliv. 2010;17(6):365–375.
   PubMed Web of Science ®Google Scholar
• van Rijn P, Böker A. Bionanoparticles and hybrid materials: tailored structural properties, self-assembly, materials and developments in the field. J Mater Chem. 2011;21(42):16735–16747.
   Web of Science ®Google Scholar
• Jutz G, Böker A. Bionanoparticles as functional macromolecular building blocks – a new class of nanomaterials. Polymer. 2011;52(2):211–232.
   Web of Science ®Google Scholar
• Kim M, Rho Y, Jin KS, et al. pH-Dependent Structures of Ferritin and Apoferritin in Solution: disassembly and Reassembly. Biomacromolecules. 2011;12(5):1629–1640.
   PubMed Web of Science ®Google Scholar
• Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res. 1994;11(8):1186–1189.
   PubMed Web of Science ®Google Scholar
• Guo X, Zhuang Q, Ji T, et al. Multi-functionalized chitosan nanoparticles for enhanced chemotherapy in lung cancer. Carbohydr Polym. 2018;195:311–320.
   PubMed Web of Science ®Google Scholar
• Suresh D, Zambre A, Mukherjee S, et al. Silencing AXL by covalent siRNA-gelatin-antibody nanoconjugate inactivates mTOR/EMT pathway and stimulates p53 for TKI sensitization in NSCLC. Nanomedicine. 2019;20:102007.
   PubMed Web of Science ®Google Scholar
• Dubruel P, Unger R, Van Vlierberghe S, et al. Porous gelatin hydrogels:  2. In Vitro Cell Interact Study. Biomacromolecules. 2007;8(2):338–344.
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Chao J, Neidhart JD, et al. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs. 2013;31(4):986–1000.
   PubMed Web of Science ®Google Scholar
• Xu G, Liu S, Niu H, et al. Functionalized mesoporous carbon nanoparticles for targeted chemo-photothermal therapy of cancer cells under near-infrared irradiation. RSC Adv. 2014;4(64):33986–33997.
   Web of Science ®Google Scholar
• Pouton CW, Wagstaff KM, Roth DM, et al. Targeted delivery to the nucleus. Adv Drug Deliv Rev. 2007;59(8):698–717.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang Y, Xu B, et al. Mesoporous carbon nanomaterials induced pulmonary surfactant inhibition, cytotoxicity, inflammation and lung fibrosis. J Environ Sci. 2017;62:100–114.
   Google Scholar
• Xie R, Lian S, Peng H, et al. Mitochondria and nuclei dual-targeted hollow carbon nanospheres for cancer chemophotodynamic synergistic therapy, mol. Pharm. 2019;16(5):2235–2248.
   Google Scholar
• Masuda M, Kawakami S, Wijagkanalan W, et al. Anti-MUC1 aptamer/negatively charged amino acid dendrimer conjugates for targeted delivery to human lung adenocarcinoma A549 cells. Biol Pharm Bull. 2016;39(10):1734–1738.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chang YQ, Han L, et al. Aptamer-anchored di-polymer shell-capped mesoporous carbon as a drug carrier for bi-trigger targeted drug delivery. J Mat Chem B. 2017;5(33):6882–6889.
   PubMed Web of Science ®Google Scholar
• Tabish TA, Pranjol MZI, Jabeen F, et al. Investigation into the toxic effects of graphene nanopores on lung cancer cells and biological tissues. Appl Mater Today. 2018;12:389–401.
   Web of Science ®Google Scholar
• Sailor MJ, Park J-H. Hybrid nanoparticles for detection and treatment of cancer, Advanced materials (deerfield beach. Fla.). 2012;24(28):3779–3802.
   Google Scholar
• Hoffmann F, Cornelius M, Morell J, et al. Silica-Based mesoporous organic–inorganic hybrid materials. Angew Chem. 2006;45(20):3216–3251.
   Google Scholar
• Rasmussen JW, Martinez E, Louka P, et al. Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications. Expert Opin Drug Deliv. 2010;7(9):1063–1077.
   PubMed Web of Science ®Google Scholar
• Kim S, Lee SY, Cho H-J. Berberine and zinc oxide-based nanoparticles for the chemo-photothermal therapy of lung adenocarcinoma. Biochem Biophys Res Commun. 2018;501(3):765–770.
   PubMed Web of Science ®Google Scholar
• Tanino R, Amano Y, Tong X, et al. Anticancer activity of ZnO nanoparticles against human small-cell lung cancer in an orthotopic mouse model. Mol Cancer Ther. 2020;19(2):502–512.
   PubMed Web of Science ®Google Scholar
• Meyer A, Oehninger L, Geldmacher Y, et al. Gold(I) N-heterocyclic carbene complexes with naphthalimide ligands as combined thioredoxin reductase inhibitors and DNA intercalators. ChemMedChem. 2014;9(8):1794–1800.
   PubMed Web of Science ®Google Scholar
• Sun Q, You Q, Pang X, et al. A photoresponsive and rod-shape nanocarrier: Single wavelength of light triggered photothermal and photodynamic therapy based on AuNRs-capped & Ce6-doped mesoporous silica nanorods. Biomaterials. 2017;122:188–200.
   PubMed Web of Science ®Google Scholar
• Cai C, Li X, Wang Y, et al. Polydopamine-coated gold core/hollow mesoporous silica shell particles as a nanoplatform for multimode imaging and photothermal therapy of tumors. Chem Eng J. 2019;362:842–850.
   Web of Science ®Google Scholar
• Au GHT, Shih WY, Shih W-H. High-conjugation-efficiency aqueous CdSe quantum dots. Analyst. 2013;138(24):7316–7325.
   PubMed Web of Science ®Google Scholar
• Jiang K, Sun S, Zhang L, et al. Red, green, and blue luminescence by carbon dots: full-color emission tuning and multicolor cellular imaging. Angew Chem. 2015;54(18):5360–5363.
   Google Scholar
• Pan L, Sun S, Zhang A, et al. Truly fluorescent excitation-dependent carbon dots and their applications in multicolor cellular imaging and multidimensional sensing. Adv Mater. 2015;27(47):7782–7787.
   PubMed Web of Science ®Google Scholar
• Zhao S, Sun S, Jiang K, et al. In situ synthesis of fluorescent mesoporous silica–carbon dot nanohybrids featuring folate receptor-overexpressing cancer cell targeting and drug delivery. Nano-Micro Lett. 2019;11(1):32.
   PubMed Web of Science ®Google Scholar
• Lu J, Liu F, Li H, et al. Width-Consistent mesoporous silica nanorods with a precisely controlled aspect ratio for lysosome dysfunctional synergistic chemotherapy/photothermal therapy/starvation therapy/oxidative therapy. ACS Appl Mater Interfaces. 2020;12(22):24611–24622.
   PubMed Web of Science ®Google Scholar
• Lin X, Zuo YY, Gu N. Shape affects the interactions of nanoparticles with pulmonary surfactant. Sci China Mater. 2015;58(1):28–37.
   PubMed Web of Science ®Google Scholar
• You Y, He L, Ma B, et al. High-Drug-Loading mesoporous silica nanorods with reduced toxicity for precise cancer therapy against nasopharyngeal carcinoma. Adv Funct Mater. 2017;27(42):1703313.
   Web of Science ®Google Scholar
• Satish S, Tharmavaram M, Rawtani D. Halloysite nanotubes as a nature’s boon for biomedical applications. Nanobiomedicine (Rij). 2019;6:1849543519863625.
   Google Scholar
• Dzamukova MR, Naumenko EA, Lvov YM, et al. Enzyme-activated intracellular drug delivery with tubule clay nanoformulation. Sci Rep. 2015;5:11.
   Web of Science ®Google Scholar
• Chen L, Qian M, Jiang H, et al. Multifunctional mesoporous black phosphorus-based nanosheet for enhanced tumor-targeted combined therapy with biodegradation-mediated metastasis inhibition. Biomaterials. 2020;236:119770.
   PubMed Web of Science ®Google Scholar
• Khatun Z, Nurunnabi M, Nafiujjaman M, et al. A hyaluronic acid nanogel for photo–chemo theranostics of lung cancer with simultaneous light-responsive controlled release of doxorubicin. Nanoscale. 2015;7(24):10680–10689.
   PubMed Web of Science ®Google Scholar
• Sánchez A, Ovejero Paredes K, Ruiz-Cabello J, et al. Hybrid decorated Core@Shell janus nanoparticles as a flexible platform for targeted multimodal molecular bioimaging of cancer. ACS Appl Mater Interfaces. 2018;10(37):31032–31043.
   PubMed Web of Science ®Google Scholar
• Gisbert-Garzarán M, Lozano D, Matsumoto K, et al. Designing mesoporous silica nanoparticles to overcome biological barriers by incorporating targeting and endosomal escape. ACS Appl Mater Interfaces. 2021;13(8):9656–9666.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu J, Chu L, et al. Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer. Int J Nanomedicine. 2010;6:59–69.
   PubMed Web of Science ®Google Scholar
• Holt GE, Daftarian P. Non-small-cell lung cancer homing peptide-labeled dendrimers selectively transfect lung cancer cells. Immunotherapy. 2018;10(16):1349–1360.
   PubMed Web of Science ®Google Scholar
• Amreddy N, Babu A, Panneerselvam J, et al. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine. 2018;14(2):373–384.
   PubMed Web of Science ®Google Scholar
• Argyo C, Weiss V, Bräuchle C, et al. Multifunctional mesoporous silica nanoparticles as a universal platform for drug delivery. Chem Mater. 2014;26(1):435–451.
   Web of Science ®Google Scholar
• Yatvin M, Weinstein J, Dennis W, et al. Design of liposomes for enhanced local release of drugs by hyperthermia. Science. 1978;202(4374):1290–1293.
   PubMed Web of Science ®Google Scholar
• Di Corato R, Béalle G, Kolosnjaj-Tabi J, et al. Combining magnetic hyperthermia and photodynamic therapy for tumor ablation with photoresponsive magnetic liposomes. ACS Nano. 2015;9(3):2904–2916.
   PubMed Web of Science ®Google Scholar
• Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics. 2020;10(10):4557–4588.
   PubMed Web of Science ®Google Scholar
• Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics. 2020;10(10):4557–4588.
   PubMed Web of Science ®Google Scholar
• Huang X, Wu S, Du X. Gated mesoporous carbon nanoparticles as drug delivery system for stimuli-responsive controlled release. Carbon. 2016;101:135–142.
   Web of Science ®Google Scholar
• Yang J, Gao F, Han D, Yang L, Kong X, Wei M, Cao J, Liu H, Wu Z, Pan G. Multifunctional zinc-based hollow nanoplatforms as a smart pH-responsive drug delivery system to enhance in vivo tumor-inhibition efficacy. Materials & Design. 2018;139:172–180.
   Web of Science ®Google Scholar
• Näkki S, Wang JTW, Wu J, et al. Designed inorganic porous nanovector with controlled release and MRI features for safe administration of doxorubicin. Int J Pharm. 2019;554:327–336.
   PubMedGoogle Scholar
• Chen T, Wu W, Xiao H, et al. Intelligent drug delivery system based on mesoporous silica nanoparticles coated with an ultra-pH-sensitive Gatekeeper and Poly(ethylene glycol. ACS Macro Lett. 2016;5(1):55–58.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang S, Song FX, et al. A pH-sensitive drug delivery system based on folic acid-targeted HBP-modified mesoporous silica nanoparticles for cancer therapy. Colloids Surf A Physicochem Eng Asp. 2020;590:124470.
   Web of Science ®Google Scholar
• Song Y, Zhou B, Du X, et al. Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC. Biomed Pharmacother. 2020;125:109561.
   PubMed Web of Science ®Google Scholar
• Cauda V, Engelke H, Sauer A, et al. Colchicine-loaded lipid bilayer-coated 50 nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell uptake. Nano Lett. 2010;10(7):2484–2492.
   PubMed Web of Science ®Google Scholar
• Fei W, Zhang Y, Han S, et al. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma. Int J Pharm. 2017;519(1–2):250–262.
   PubMed Web of Science ®Google Scholar
• Mackowiak SA, Schmidt A, Weiss V, et al. Targeted drug delivery in cancer cells with red-light photoactivated mesoporous silica nanoparticles. Nano Lett. 2013;13(6):2576–2583.
   PubMed Web of Science ®Google Scholar
• He Y, Su Z, Xue L, et al. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy. J Control Release. 2016;229:80–92.
   PubMed Web of Science ®Google Scholar
• Ji F, Sun H, Qin Z, et al. Engineering polyzwitterion and polydopamine decorated doxorubicin-loaded mesoporous silica nanoparticles as a ph-sensitive drug delivery. Polymers. 2018;10(3):326.
   PubMed Web of Science ®Google Scholar
• Joshi N, Shirsath N, Singh A, et al. Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: Pulmonary compatible and site-specific drug delivery in lung metastases. Sci Rep. 2014;4(1):7085.
   PubMedGoogle Scholar
• Blair SL, Heerdt P, Sachar S, et al. Glutathione metabolism in patients with non-small cell lung cancers. Cancer Res. 1997;57(1):152–155.
   PubMed Web of Science ®Google Scholar
• Gamcsik MP, Kasibhatla MS, Teeter SD, et al. Glutathione levels in human tumors. Biomarkers. 2012;17(8):671–691.
   PubMed Web of Science ®Google Scholar
• Chaiswing L, St Clair WH, St Clair DK. Redox paradox: A novel approach to therapeutics-resistant cancer. Antioxid Redox Signal. 2018;29(13):1237–1272.
   PubMed Web of Science ®Google Scholar
• Tang ZM, Zhang L, Wang Y, et al. Redox-responsive star-shaped magnetic micelles with active-targeted and magnetic-guided functions for cancer therapy. Acta Biomater. 2016;42:232–246.
   PubMed Web of Science ®Google Scholar
• Zhou J, Hao NJ, De Zoyza T, et al. Lectin-gated, mesoporous, photofunctionalized glyconanoparticles for glutathione-responsive drug delivery. Chem Comm. 2015;51(48):9833–9836.
   PubMed Web of Science ®Google Scholar
• Song Y, Cai H, Yin T, et al. Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment. Int J Nanomedicine. 2018;13:1585–1600.
   PubMed Web of Science ®Google Scholar
• Guo F, Wu J, Wu W, et al. PEGylated self-assembled enzyme-responsive nanoparticles for effective targeted therapy against lung tumors. J Nanobiotechnology. 2018;16(1):57.
   PubMedGoogle Scholar
• He Y, Lei L, Cao J, et al. A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting. Sci Adv. 2021;7(6):eaba0776.
   PubMed Web of Science ®Google Scholar
• Cho I-H, Shim MK, Jung B, et al. Heat shock responsive drug delivery system based on mesoporous silica nanoparticles coated with temperature sensitive gatekeeper. Microporous Mesoporous Mater. 2017;253:96–101.
   Web of Science ®Google Scholar
• Cui Y, Deng R, Li X, et al. Temperature-sensitive polypeptide brushes-coated mesoporous silica nanoparticles for dual-responsive drug release. Chin Chem Lett. 2019;30(12):2291–2294.
   Web of Science ®Google Scholar
• Hwang HS, Shin H, Han J, et al. Combination of photodynamic therapy (PDT) and anti-tumor immunity in cancer therapy. J Pharm Invest. 2018;48(2):143–151.
   PubMedGoogle Scholar
• Hester SC, Kuriakose M, Nguyen CD, et al. Role of ultrasound and photoacoustic imaging in photodynamic therapy for Cancer. Photochem Photobiol. 2020;96(2):260–279.
   PubMed Web of Science ®Google Scholar
• Li D, Zhang T, Min C, et al. Biodegradable theranostic nanoplatforms of albumin-biomineralized nanocomposites modified hollow mesoporous organosilica for photoacoustic imaging guided tumor synergistic therapy. Chem Eng J. 2020;388:124253.
   Web of Science ®Google Scholar
• Wang Y, Wang L, Guo L, et al. Photo-responsive magnetic mesoporous silica nanocomposites for magnetic targeted cancer therapy. New J Chem. 2019;43(12):4908–4918.
   Web of Science ®Google Scholar